Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GYRE THERAPEUTICS, INC.CBIO · Entity 5247 | Director | August 31, 2023 | September 01, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GYRE THERAPEUTICS, INC.
Report date August 31, 2023 · Filed September 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series Y Preferred StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-08-31 transaction · row 1
1 source rowRow 1 · 2023-08-31 · Disposition to issuer · Disposed 28.228 · Balance 0 F1: On June 20, 2023, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. F2: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 20, 2023, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company.
F2: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2023 Filed Sep 1, 2023 20:07 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | Disposition to issuerSeries Y Preferred Stock | 28.228 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-042368 · form4.xml · nonDerivative · entry 1 Hunt Andrea · CIK 0001720487 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: On June 20, 2023, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. F2 · shares: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated. F2 · price: On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated. Read SEC document |
| January 07, 2022 Filed Jan 7, 2022 22:30 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 7,521 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002482 · doc4.xml · nonDerivative · entry 1 Hunt Andrea · CIK 0001720487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,228 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:32 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-059427 · doc4.xml · nonDerivative · entry 1 Hunt Andrea · CIK 0001720487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,707 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 13:53 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 2,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-044689 · doc4.xml · nonDerivative · entry 1 Hunt Andrea · CIK 0001720487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,883 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| June 09, 2021 Filed Jul 2, 2021 13:53 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001209191-21-044689 · doc4.xml · derivative · entry 2 Hunt Andrea · CIK 0001720487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2031-06-09 F2 · derivative.exercise_date: 100% of the shares subject to the option will vest and become exercisable on June 9, 2022, the one-year anniversary of the grant date. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 17:37 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 2,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-025030 · doc4.xml · nonDerivative · entry 1 Hunt Andrea · CIK 0001720487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,997 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 21:56 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002161 · doc4.xml · nonDerivative · entry 1 Hunt Andrea · CIK 0001720487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,517 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 20:18 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 2,761 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-053119 · doc4.xml · nonDerivative · entry 1 Hunt Andrea · CIK 0001720487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,636 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:42 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 2,076 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-040386 · doc4.xml · nonDerivative · entry 1 Hunt Andrea · CIK 0001720487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,875 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 20:45 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.18 | $0.00 |
DisclosureSEC source: 0001209191-20-036312 · doc4.xml · derivative · entry 1 Hunt Andrea · CIK 0001720487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2030-06-11 F1 · derivative.exercise_date: The option shall vest monthly over a period of 12 months commencing June 11, 2020. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:39 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,673 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-023182 · doc4.xml · nonDerivative · entry 1 Hunt Andrea · CIK 0001720487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,799 F1 · shares: Represents shares of common stock received in lieu of fees. Read SEC document |
| January 02, 2020 Filed Jan 2, 2020 21:45 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,073 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-000337 · doc4.xml · nonDerivative · entry 1 Hunt Andrea · CIK 0001720487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,126 F1 · shares: Represents shares of stock received in lieu of fees. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 20:07 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,489 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051614 · doc4.xml · nonDerivative · entry 1 Hunt Andrea · CIK 0001720487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,053 F1 · shares: Represents shares of stock received in lieu of fees. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 20:49 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 1,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-040358 · doc4.xml · nonDerivative · entry 1 Hunt Andrea · CIK 0001720487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,564 F1 · shares: Represents shares of stock received in lieu of fees. Read SEC document |
| June 13, 2019 Filed Jun 18, 2019 01:08 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.46 | $0.00 |
DisclosureSEC source: 0001209191-19-037568 · doc4.xml · derivative · entry 1 Hunt Andrea · CIK 0001720487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-06-13 F1 · derivative.exercise_date: The option shall vest monthly over a period of 12 months commencing June 13, 2019. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 20:37 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 717 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-022530 · doc4.xml · nonDerivative · entry 1 Hunt Andrea · CIK 0001720487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,528 F1 · shares: Represents shares of stock received in lieu of fees. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 22:44 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantCommon Stock | 811 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001219 · doc4.xml · nonDerivative · entry 1 Hunt Andrea · CIK 0001720487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 811 F1 · shares: Represents shares of stock received in lieu of fees. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 21:53 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $24.94 | $0.00 |
DisclosureSEC source: 0001209191-18-038136 · doc4.xml · derivative · entry 1 Hunt Andrea · CIK 0001720487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: The option shall vest monthly over a period of 12 months commencing June 13, 2018. Read SEC document |
| October 25, 2017 Filed Oct 27, 2017 01:28 UTC | GYRE THERAPEUTICS, INC. CBIO · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001209191-17-058099 · doc4.xml · derivative · entry 1 Hunt Andrea · CIK 0001720487 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-10-25 F1 · derivative.exercise_date: The Option shall vest monthly over a period of three years commencing October 25, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.